Vulvar Intraepithelial Neoplasia (VIN)

Here’s the RoshReview Question of the Week!

A 41-year-old woman, G2P2, presents to your office for postcoital bleeding. She has a history of laparoscopic hysterectomy for persistent cervical intraepithelial neoplasia 3. A vaginoscopy is performed and shows multiple lesions in the upper third of the vagina. One lesion located within a suture recess near the vaginal cuff is not able to be visualized in its entirety. Biopsy reveals a high-grade squamous epithelial lesion. Her social history is significant for smoking. Which of the following is the best therapy?

Check your answer at the links above and check out RoshReview’s CREOG question bank!


Follow along with ACOG CO 675!

What is Vulvar Squamous Intraepithelial Lesions (SIL) and why do we care? - previously called VIN 

  • VIN is increasingly common - esp in women in their 40s 

    • VIN has increased more than 4x from 1973 to 2000! 

    • VIN should be considered a premalignant condition

  • How do we classify?

    • Has changed a lot over time, but most recently we have used:

      • LSIL of the vulva - used for low grade changes that come from HPV infections (usually present as genital warts) 

      • HSIL of the vulva - used for high grade changes that comes from HPV infections (precancerous lesions) - used to be called “usual type” 

        • VIN, warty type 

        • VIN, basaloid type 

        • VIN, mixed (warty or basaloid) type 

      • Differentiated type - from things like lichen sclerosus 

    • The International Society for the Study of Vulvovaginal Disease ISSVD recommends these terms to unify the nomenclature of HPV-associated squamous lesions of the lower genital tract - all of these are based on histopathologic findings:

ACOG CO 675

How do we diagnose VIN? 

  • Unfortunately, no good screening strategies

    • Detection usually limited to visual inspection 

    • What does it look like?

      • Can vary. Most will be raised, but some can be flat 

      • Discoloration of the skin - white, gray, red, brown, or even black 

    •  Should biopsy to make definitive diagnosis if not sure of diagnosis of something else (ie. LS) 

      • Biopsy should be performed in postmenopausal women with apparent genital warts and in women of all ages with genital warts where topical therapies have failed 

      • Colpo can also be useful - just remember that you need to soak the vulva in acetic acid with a gauze pad for several minutes 

What do we do to treat? 

  • Treat all vulvar HSIL (VIN usual type) 

    • Surgery 

      • Wide local excision should be done if there is suspected to be cancer 

      • Can be occult invasion even if initial biopsy is vulvar HSIL 

      • Should include gross margin of 0.5-1 cm around tissue with visible disease 

      • May be altered to avoid injury to critical structures like clitoris, urethra, anus, or other structures 

      • However, if lesions in critical areas, should be referred to specialist to avoid impaired psychosexual function (ie. if extensive around the perineum, reaching back to anus or around the clitoris 

      • If clear margins in excised tissue, much lower risk of recurrence 

    • Laser Ablation Therapy 

      • Should be done if occult invasion is not a concern

      • Can be used for single, multifocal, or confluent lesions, although risk of recurrence may be higher than with excision 

      • Colpo can help delineate lesions of margins 

      • As with excision, 0.5-1cm margin to be treated 

      • Remember than unlike genital warts, the entire thickness of the epithelium must be treated

    • Medical Therapy 

      • Topical imiquimod 5% 

      • Regimens that have been published include 3x/week to affected area for 12-20 weeks 

      • Colpo assessment at 4-6 weeks 

      • Residual lesions require surgical treatment 

  • Surveillance

    • Recurrence rate is as high as 9-50% with all treatment regimens

      • Higher with positive margins

      • Lower in surgically treated patients 

    •  Follow up has been limited in most studies 

    • However, women with Vulvar HSIL are at high risk of recurrence during their life time 

    • If complete response to therapy and no new lesions at follow-up visits, scheduled 6 and 12 months after initial treatment should be monitored by visual inspection